Valion Bio, Inc. (VBIO): Capital Expenditures
$38.0K
Year ended 2025-12-31
$99.0K
Trailing 12 months to 2026-06-30
+51.2%
3-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $38.0K | n/a | 2026-03-30, From 2025-01-01 |
| 2024-12-31 | $0 | -100.0% | 2026-03-30, From 2024-01-01 |
| 2023-12-31 | $118.0K | +972.7% | 2025-03-21, From 2023-01-01 |
| 2022-12-31 | $11.0K | n/a | 2024-03-25, From 2022-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| Valion Bio, Inc. (VBIO) | 2025-12-31 | $38.0K | n/a |
| Equillium, Inc. (EQ) | 2025-12-31 | $48.0K | -43.5% |
| Tvardi Therapeutics, Inc. (TVRD) | 2024-12-31 | $1.05M | -56.0% |
| China Pharma Holdings, Inc. (CPHI) | 2025-12-31 | $59.3K | +54.4% |
| Dare Bioscience, Inc. (DARE) | 2025-12-31 | $385.3K | -32.8% |
| PDS Biotechnology Corp (PDSB) | 2025-12-31 | $0 | -100.0% |
| Yarrow Bioscience, Inc. (YARW) | 2025-12-31 | $0 | -100.0% |
| Sunshine Biopharma Inc. (SBFM) | 2025-12-31 | $174.5K | -89.5% |
| Sol-Gel Technologies Ltd. (SLGL) | 2025-12-31 | $47.0K | n/m |
Compare VBIO, EQ, TVRD, CPHI side by side · Screen every company in Pharmaceutical Preparations ↗